دورية أكاديمية

Assessment of Serum Nitrogen Species and Inflammatory Parameters in Relapsing-Remitting Multiple Sclerosis Patients Treated with Different Therapeutic Approaches.

التفاصيل البيبلوغرافية
العنوان: Assessment of Serum Nitrogen Species and Inflammatory Parameters in Relapsing-Remitting Multiple Sclerosis Patients Treated with Different Therapeutic Approaches.
المؤلفون: Niedziela, Natalia, Adamczyk-Sowa, Monika, Niedziela, Jacek T., Mazur, Bogdan, Kluczewska, Ewa, Sowa, Paweł, Gąsior, Mariusz
المصدر: BioMed Research International; 12/19/2016, Vol. 2016, p1-11, 11p
مصطلحات موضوعية: THERAPEUTIC use of interferons, MULTIPLE sclerosis treatment, ACADEMIC medical centers, BIOMARKERS, C-reactive protein, CHI-squared test, IMMUNOLOGICAL adjuvants, INFLAMMATION, INTERFERONS, INTERLEUKINS, LONGITUDINAL method, MAGNETIC resonance imaging, MULTIPLE sclerosis, NITRIC oxide, PROBABILITY theory, STATISTICS, DATA analysis, TREATMENT effectiveness, CASE-control method, REACTIVE nitrogen species, DATA analysis software, DESCRIPTIVE statistics, NATALIZUMAB, MANN Whitney U Test, KRUSKAL-Wallis Test
مصطلحات جغرافية: POLAND
مستخلص: The role of nitric oxide and its reactive derivatives (NOx) is well known in the pathogenesis of multiple sclerosis, which is an inflammatory disease while NOx seems to be important in coordinating inflammatory response. The purpose of the present study was to assess serum NOx as one of the nitrogen species and inflammatory parameters in relapsing-remitting multiple sclerosis patients and to compare the effectiveness of various types of disease-modifying therapies that reduce nitric oxide and inflammatory biomarkers. Elevated NOx level was observed in patients who received the first-line disease-modifying therapy (interferons beta-1a and beta-1b) in comparison with the subjects treated with the second-line disease-modifying therapy (natalizumab; fingolimod) and healthy controls without significant differences in C-reactive protein and interleukin-1 beta. A negative correlation was observed between serum NOx level and the duration of multiple sclerosis confirmed in the whole study population and in subjects treated with the first-line agents. Only serum NOx, concentration could reveal a potential efficacy of disease-modifying therapy with a better reduction in NOx level due to the second-line agents of disease-modifying therapy. [ABSTRACT FROM AUTHOR]
Copyright of BioMed Research International is the property of Hindawi Limited and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:23146133
DOI:10.1155/2016/4570351